About WIN 2014 Symposium
Richard L. Schilsky, Chairman Scientific Advisory Board WIN Consortium. About changes that are needed in research, development and registration of precision cancer medicine.
Dr John Mendelsohn (The University of Texas MD Anderson Cancer Center, Houston, USA), Dr Razelle Kurzrock (Moores Cancer Center, San Diego, USA) and Dr Mace Rothenberg (Pfizer Inc., New York, USA) about the goals of the WIN consortium and how these fields are highlighted at the annual WIN Symposium in Paris.
The WIN 2014 Symposium which was held in Paris, June 23 and 24, 2014, was an exceptional global event entirely dedicated to breakthrough biomarker investigations and combination therapies for cancer. Over 400 delegates from more than 35 countries worldwide attended the Symposium and heard presentations by global key opinion leaders such as Robert Weinberg, Leroy Hood, Bob Löwenberg, Olli Kallioniemi, René Bernards, Guido Kroemer, Hans Clevers and others. Many presentations can be downloaded in PDF format or be viewed as webcasts on this website.
95 abstracts were submitted, of which 84 were scheduled for poster presentation. Two posters were selected to receive a best-poster award, one by a group of Spanish researchers and one from Australia. Many posters can be downloaded as e-posters. Abstracts are available online on this website only.
The next WIN Symposium is scheduled to take place in Paris, June 29-30, 2015. Further details will be announced on this website as they become available. To ensure that you are on the mailing list for further announcements, send you name and email address to the Symposium Secretariat (firstname.lastname@example.org).
Most patients’ tumors are driven by multiple molecular aberrations that cannot be controlled by a single targeted agent. The challenge is to identify and test smart combinations of targeted agents capable of blocking optimal pathways at the same time.
- John Mendelsohn, Chair of the WIN Consortium
This original theme is for the first time the subject of an international symposium. Join the world’s leaders in precision cancer medicine: René Bernards, Leroy Hood, Bob Löwenberg, Richard Schilsky, Razelle Kurzrock, Ross Levin, Jean-Charles Soria, and many others.
- Vladimir Lazar, Chief Operating Officer of WIN Consortium
Some combinations are currently under investigation. Results of these and additional clinical studies are eagerly awaited as they hold the promise of taking precision cancer medicine to the next level.
- Alexander Eggermont, Vice-Chair WIN Consortium and Co-Chair WIN 2014 Symposium